{"url_path":"/sec/eltx/8-k/2026-06-17/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1601485/0001601485-26-000048-index.html","accession_number":"0001601485-26-000048","cik":"0001601485","ticker":"ELTX","issuer_name":"Elicio Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1601485/0001601485-26-000048-index.html","primary_entity_key":"0001601485","primary_entity_name":"Elicio Therapeutics, Inc."},"word_count":82,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits.\n\nExhibit NumberExhibit\nDescription\n\n99.1\n[Press Release dated June 17, 2026.](a2026-06x17xxeltxxxmulti.htm)\n\n104Cover Page Interactive Data File (embedded within the Inline XBRL document)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nElicio Therapeutics, Inc.\n\nBy:/s/ ROBERT CONNELLY\n\nDate: June 17, 2026\n\nRobert Connelly\n\nPresident and Chief Executive Officer\n\n(Principal Executive Officer)"}